Assessing the Effect of High Performance Inulin Supplementation via KLF5 mRNA Expression in Adults with Type 2 Diabetes: A Randomized Placebo Controlled Clinical Trail

Study answer

What this study found

HP inulin 10 g/day significantly lowered fasting plasma glucose vs placebo (P<0.001). KLF5 mRNA expression in PBMCs decreased (fold change 0.61 ± 0.11; P=0.001). Plasma miR-375 increased (fold change 3.75 ± 0.70; P=0.004). No significant between-group differences for HbA1c, fasting insulin, lipids, weight, or BMI; waist and hip circumference decreased within the HP inulin group. Interpretation: HP inulin may support glycemic control in type 2 diabetes by modulating KLF5 and miR-375; further larger and longer studies are needed to confirm and clarify mechanisms.

Study & population

Randomized, double-blind, placebo-controlled clinical trial in adults with type 2 diabetes; 46 participants aged 30–50 years were randomly allocated to HP inulin (n=23) or placebo (n=23) for 6 weeks, using randomized block procedure with stratification by gender and age.

Intervention

HP inulin powder, 10 g per day, divided into two 5 g doses taken before breakfast and before dinner, for 6 weeks.

Key limitation

Small sample size; short duration (6 weeks); limited biomarker scope (no inflammatory markers, short-chain fatty acids, or other glucose-regulation genes).

View full study detailsView sourceOpen PDF

Original abstract